Your browser doesn't support javascript.
loading
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
Choudhary, Manish C; Chew, Kara W; Deo, Rinki; Flynn, James P; Regan, James; Crain, Charles R; Moser, Carlee; Hughes, Michael D; Ritz, Justin; Ribeiro, Ruy M; Ke, Ruian; Dragavon, Joan A; Javan, Arzhang Cyrus; Nirula, Ajay; Klekotka, Paul; Greninger, Alexander L; Fletcher, Courtney V; Daar, Eric S; Wohl, David A; Eron, Joseph J; Currier, Judith S; Parikh, Urvi M; Sieg, Scott F; Perelson, Alan S; Coombs, Robert W; Smith, Davey M; Li, Jonathan Z.
Afiliación
  • Choudhary MC; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Chew KW; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Deo R; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Flynn JP; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Regan J; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Crain CR; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Moser C; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Hughes MD; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Ritz J; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Ribeiro RM; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
  • Ke R; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
  • Dragavon JA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Javan AC; National Institutes of Health, Bethesda, MD, USA.
  • Nirula A; Lilly Research Laboratories, San Diego, CA, USA.
  • Klekotka P; Lilly Research Laboratories, San Diego, CA, USA.
  • Greninger AL; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Fletcher CV; Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.
  • Daar ES; Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
  • Wohl DA; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
  • Eron JJ; Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
  • Currier JS; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
  • Parikh UM; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Sieg SF; Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH, USA.
  • Perelson AS; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.
  • Coombs RW; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Smith DM; Department of Medicine, University of California, San Diego, CA, USA. davey@ucsd.edu.
  • Li JZ; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jli@bwh.harvard.edu.
Nat Microbiol ; 7(11): 1906-1917, 2022 11.
Article en En | MEDLINE | ID: mdl-36289399
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Nat Microbiol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Nat Microbiol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido